Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart in psoriatic arthritis
2025-520997-21-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing tulisokibart with placebo to MK-7240 (2 arms). Primary endpoint: ACR20 at Week 16. Planned start May 2026; status: authorised.
02
Drugs
tulisokibart
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2025-520997-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520997-21-00.